PTPA and posterior cortical atrophy: Together, these results demonstrate that the loss of LCMT1/decreased PP2A-C α-carboxymethylation is a major determinant of AR-addicted PCa and supports the therapeutic use of AR degraders and selective small molecule modulators of PP2A for refractory prostate cancer treatment.